Across TCGA pan-cancer cohorts, RPL17P14 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated RPL17P14 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RPL17P14 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL17P14 expression acts as an unfavorable survival marker.

STAD, KIRC, and OV are the cancer types where RPL17P14 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	II,III,IV	0.341	0.570	<.001	141	view →
KIRC	DFS	Tertile	All	0.463	0.805	.001	96	view →
OV	OS	Tertile	III,IV	0.648	0.844	.011	60	view →
SKCM	DFS	Tertile	All	0.015	0.758	<.001	54	view →
KIRP	DFS	Tertile	IV	0.088	0.502	<.001	45	view →
BRCA	DFS	Tertile	II,III,IV	0.752	0.893	.002	42	view →
PAAD	OS	Tertile	All	0.230	0.594	.004	36	view →
LUAD	DFS	Tertile	III,IV	0.199	0.640	.003	36	view →
UCEC	OS	Tertile	All	0.850	0.929	.001	36	view →
UVM	OS	Tertile	All	0.220	0.917	<.001	27	view →
GBM	OS	Tertile	All	0.153	0.431	.003	18	view →
COAD	DFS	Tertile	III,IV	0.151	0.616	.028	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

Exploration

Same gene, other analysis: RPL17P14 tumor-vs-normal RNA expression · all RPL17P14 data types